Investigational drug · Phase 2
SHR3680
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
20
Any phase or sponsor naming "SHR3680"
First trial start
2025
Dec 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR3680", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR3680" as an intervention, largest first.
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03520478 · 654 participants · Start May 30, 2018 · Primary completion Apr 30, 2023
Drug: SHR3680; Bicalutamide · For: Prostate Cancer; Hormone-Dependent Prostate Cancer
Sites: Burgas, Bulgaria; Dobrich, Bulgaria; Gabrovo, Bulgaria · 67 sites in all
- A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical ProstatectomyPivotal-lookingTerminated
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05009290 · 391 participants · Start Nov 1, 2021 · Primary completion Sep 6, 2024
Drug: SHR3680; Placebo · For: Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Sites: Shanghai, China
Fudan UniversityAcademic, hospital or other
NCT04355858 · 319 participants (planned) · Start May 1, 2020 · Primary completion May 1, 2023
Drug: SHR7390; Famitinib and 13 more · For: Breast Cancer; Metastatic Cancer
Sites: Shanghai, China
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07230106 · 218 participants (planned) · Start Dec 8, 2025 · Primary completion Dec 2028
Drug: HS-20093 for Injection; SHR3680 Tablet and 4 more · For: Prostate Cancer
Sites: Nanjing, China; Tianjin, China
- A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer PatientsStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT02691975 · 197 participants · Start Apr 12, 2016 · Primary completion Dec 1, 2020
Drug: SHR3680 · For: Hormone Refractory Prostate Cancer; Metastatic Prostate Carcinoma
Sites: Beijing, China; Chongqing, China; Zhenzhou, China · 12 sites in all
- A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPCPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04603833 · 150 participants (planned) · Start Dec 2, 2020 · Primary completion Oct 1, 2022
Drug: SHR3680+Docetaxel; SHR3680 and 1 more · For: Prostate Cancer Metastatic
Sites: Chengdu, China
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknown
Fudan UniversityAcademic, hospital or other
NCT03805399 · 140 participants (planned) · Start Oct 18, 2018 · Primary completion Dec 1, 2022
Drug: Pyrotinib with Capecitabine; AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4) and 5 more · For: Triple-negative Breast Cancer
Sites: Shanghai, China
- An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)Pivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT05928780 · 125 participants (planned) · Start Jul 1, 2023 · Primary completion Mar 1, 2024
Drug: A1:SG with SHR3680; A2:SG and 6 more · For: TNBC - Triple-Negative Breast Cancer
- Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate CancerPivotal-lookingRecruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT06305832 · 102 participants (planned) · Start Sep 7, 2023 · Primary completion Mar 2028
Drug: Rezvilutamide; Androgen deprivation therapy (ADT) · For: Prostate Cancer; Biochemical Recurrence
Sites: Nanjing, China · 2 sites in all
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT05753566 · 96 participants (planned) · Start Mar 2023 · Primary completion Mar 2027
Drug: Rezvilutamide; Androgen deprivation therapy (ADT) · For: Prostate Cancer; Biochemical Recurrence
Sites: Nanjing, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients.
Dai T, Xu Z, Huang L, et al. · Br J Clin Pharmacol 2023
- Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
Qin X, Ji D, Gu W, et al. · BMC Med 2022
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.